| Identification | Back Directory | [Name]
FPL 62064 | [CAS]
103141-09-9 | [Synonyms]
FPL 62064
N-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine
1H-Pyrazol-3-amine,N-(4-methoxyphenyl)-1-phenyl- | [Molecular Formula]
C16H15N3O | [MDL Number]
MFCD00877802 | [MOL File]
103141-09-9.mol | [Molecular Weight]
265.31 |
| Chemical Properties | Back Directory | [Boiling point ]
442.6±25.0 °C(Predicted) | [density ]
1.15±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,Room Temperature | [solubility ]
DMSO: 250 mg/mL (942.29 mM) | [form ]
Solid | [pka]
2.42±0.50(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
FPL 62064 is a potent 5-lipoxygenase (5-LOX) and COX dual inhibitor, with IC50 values of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase (cyclooxygenase), respectively. FPL 62064 has potent anti-inflammatory activity[1][2]. | [in vivo]
FPL 62064 (5-20 mg/kg; intraperitoneal injection; female LACA mice) treatment inhibits peritoneal inflammation induced by immune-complex[1]. | Animal Model: | Female LACA mice (20-30 g) injected with immune complex[1]. | | Dosage: | 5 mg/kg, 10 mg/kg, 20 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Produced a dose-related inhibition of dye extravasation, leukotriene C4 (LTC4) and prostaglandin E2 (PGE2) formation. |
| [References]
[1] Blackham A, et al. FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42. DOI:10.1007/BF01966309
[2] Shabaan MA, et al. Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase. Arch Pharm (Weinheim). 2020 Feb 7:e1900308. DOI:10.1002/ardp.201900308 |
|
| Company Name: |
BePharm Ltd
|
| Tel: |
400-685-9117 |
| Website: |
www.bepharm.com |
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList927327/0.htm |
|